Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Seven Days, Seven DAOs: Proposal for Governance and Market Flows

Seven Days, Seven DAOs: Proposal for Governance and Market Flows

BeInCryptoBeInCrypto2025/09/15 02:26
By:Linh Bùi

From Scroll’s governance suspension to Hyperliquid’s USDH battle and Ronin’s Ethereum migration, this week’s DAO proposals could reshape liquidity, incentives, and investor sentiment across DeFi.

Seven major DAO proposals emerged during a turbulent week, including Scroll’s governance shift and the USDH ticker dispute on Hyperliquid. Strategic moves from Ronin and dYdX also contributed to the significant proposals.

These decisions impact their respective ecosystems and could directly affect investors.

DAOs Heat This Week

Over the past seven days, key proposals and debates across major DAOs have painted a volatile picture of on-chain governance. From a Layer-2 (L2) project suspending its DAO operations to crucial votes deciding the future of stablecoins and buyback trends being considered by multiple protocols, the DAO market is hotter than ever.

One of the most shocking announcements came from Scroll, which revealed it would suspend its DAO and change to a more centralized model. This move raises significant questions about the balance between development speed and the philosophy of decentralization. In an era where L2 networks are fiercely competitive, Scroll’s “taking the reins” could allow faster upgrades — but also stir community concerns over transparency and user participation.

The second central focal point is the validator vote on Hyperliquid (HYPE) to determine ownership of the USDH ticker — one of the platform’s most liquid stablecoins. If control ends up in the hands of a specific group, it could directly impact stablecoin development strategies and trading fees. This battle may reshape capital flows on Hyperliquid and influence the broader DeFi ecosystem.

Seven Days, Seven DAOs: Proposal for Governance and Market Flows image 0USDH ticker war. Source:
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs